Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC

Summary

The main purpose of this study is to determine how 2 doses mirvetuximab soravtansine affects the amount and activity of folate receptor alpha proteins in tumor cells of patients who have completed standard neoadjuvant treatment and are scheduled to have their tumors surgically removed.

Timeline

Start

2017-04-17

Primary completion

2018-02-28

Completion

2018-02-28

Drugs

Indications